Therapeutic device for pathogenic virus and hematologic cancer

Abstract

To provide a physical therapeutic method as a method for treating hepatitis B virus, hepatitis C virus, leukemia, and malignant lymphoma.SOLUTION: There is provided a therapeutic system which implements a method for physically treating a pathogenic virus such as hepatitis virus, and hematologic cancers of leukemia and malignant lymphoma, in which a venous blood is taken out from a venous blood vessel using a silicone tube (1), after adding a heparin (2) the venous blood enters into a container (3) for heating at about 55°C to 60°C, an ozone (5) is added into the blood while circulating in a blood compatible metal tube (4), the blood flows out of the heating container (3) after the circulation and then the blood enters into the container (6) for returning the temperature back to the temperature about 1°C higher than an individual basal body temperature, the venous blood flows through the spread blood compatible metal tube (4), and the blood flows out of the container to return into a human body.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] Hepatitis B and C viruses, and physical therapy as a treatment for leukemia and malignant lymphoma. [Background technology]

[0002] Treatments for hepatitis B virus and hepatitis C virus include interferon, pegylated interferon, and nucleic acid analogues. Treatments for leukemia and malignant lymphoma include chemotherapy, molecular targeted therapy, radiation therapy, and hematopoietic stem cell transplantation. [Prior art documents]

[0003] [Patent Document 1] Reference number 1993-12-30 Comprehensive sterilization system [Non-patent literature]

[0004] [Non-patent literature] Summary of the Invention [Problem to be solved by the invention]

[0005] Treatments for hepatitis B virus and hepatitis C virus include interferon, pegylated interferon, and nucleic acid analogs. Treatments for leukemia and malignant lymphoma include chemotherapy, interferon, molecular targeted therapy, radiation therapy, and hematopoietic stem cell transplantation. Side effects of interferon include fever, muscle pain, joint pain, and headache, along with gastrointestinal symptoms such as loss of appetite and vomiting. Side effects of nucleic acid analogs include decreased liver function and decreased bone density. Side effects of radiation therapy include loss of appetite, diarrhea, fatigue, frequent urination, anemia, and leukopenia. [Means for solving the problem]

[0006] The comprehensive sterilization system I applied for, Patent Document 1, serial number 1993-12-30, was primarily focused on AIDS, and was a system that killed venous blood by removing it from the body and heating it, adding heparin, acetylcholine, and CO2 to the blood. I preferred ozone instead of CO2, and I was "scary" because I thought AIDS might be a genetically modified biological weapon, so I didn't include any diagrams. I filed a new application for the idea I applied for, as I thought it could be applied to various pathogenic viruses and blood-borne cancers. This is a physical treatment method for pathogenic viruses such as hepatitis virus and blood cancers such as leukemia and malignant lymphoma. Venous blood is taken out of the venous blood vessels through a silicone tube (1) and immediately added with heparin (2). The venous blood then enters a container (3) that heats it to about 55-60°C. Ozone (5) is added to the blood as it circulates through a blood-compatible metal tube (4). After circulating further, the blood leaves the heated container (3) and enters a container (6) that returns the blood to a temperature about 1°C higher than the individual's basal body temperature. The blood then passes through a network of blood-compatible metal tubes (4), leaves the container, and is returned to the body. This system can increase the effectiveness of the treatment of pathogenic viruses and blood cancers. [Effects of the Invention]

[0007] Drug therapy and radiation therapy are used to treat pathogenic viruses such as hepatitis viruses and blood cancers such as leukemia and malignant lymphoma. Side effects include gastrointestinal symptoms such as loss of appetite and vomiting. A drug-free treatment for the above diseases involves heating venous blood to around 65°C, which activates the immune system. Ozone is then added to the blood to cleanse the venous blood, a physical treatment that results in almost no side effects. [Brief explanation of the drawings]

[0008] [Figure 1] Illustrative diagram of the basic structure of this patent [Figure 2] An explanatory diagram of the location of the container where water-soluble Avigan is added [Figure 3] Diagram of where to add p53 protein [Figure 4] Diagram of serine / threonine residues and where p300 / CBP is added [Figure 5] Illustration of where to add Artemether (10) BEST MODE FOR CARRYING OUT THE INVENTION

[0009] Example 1

[0010] This physical treatment method kills pathogenic viruses such as hepatitis and blood cancers such as leukemia and malignant lymphoma. Venous blood is withdrawn from the venous veins through a silicone tube (1), immediately treated with heparin (2), and then transferred to a heated vessel (3) at approximately 55-60°C. Ozone (5) is added to the blood as it circulates through a hemocompatible metal tube (4). After circulating further, the blood exits the heated vessel (3) and enters a vessel (6) where the blood is returned to a temperature approximately 1°C above the individual's basal body temperature. The blood then passes through a network of hemocompatible metal tubes (4), exits the vessel, and is returned to the body. This system kills pathogenic viruses and blood cancers. Furthermore, the warming of the blood stimulates the immune system, and the addition of ozone cleanses the blood, improving immune and antioxidant capabilities. Figure 1 shows an example of the proposed method, with the heated container (3) and the container (6) for returning the water to room temperature both containing concentrated salt water (9). The two containers are each equipped with two temperature sensors (10) to control the temperature inside each container. Example 2

[0011] The effectiveness of this physical treatment method for pathogenic viruses such as hepatitis and blood cancers such as leukemia and malignant lymphoma can be further enhanced by adding water-soluble Avigan C5H4FN3O2 (7) to the container (6) used to return the system to room temperature. Avigan has the effect of suppressing the growth of pathogenic viruses and cell proliferation, and therefore "suppressing the growth of cancer," so water-soluble Avigan is added to venous blood. Figure 2 is an explanatory diagram of where Avigan is added to the container (6) to return it to room temperature. Example 3

[0012] In a method for physically treating blood cancers such as leukemia and malignant lymphoma, the therapeutic effect of blood cancers such as leukemia and malignant lymphoma can be further improved by adding p53 protein (8) to the rear blood-compatible metal tube (2) in the heating container (3). p53 can promote apoptosis of malignant cells. FIG. 3 is an explanatory diagram of the location where p53 protein (8) is added in the "final" blood-compatible metal tube (2) in the container (3) to be heated. Example 4

[0013] In a method for physically treating blood cancers such as leukemia and malignant lymphoma, the therapeutic effect of blood cancers such as leukemia and malignant lymphoma can be further enhanced by adding serine / threonine residues and p300 / CBP (9) to the rear blood-compatible metal tube (2) in the heated container (3). The serine / threonine residues and p300 / CBP (9) can promote the activation of p53. FIG. 4 is an illustration of the location of the serine / threonine residues and p300 / CBP (9) in the rear hemocompatible metal tube (2) in the heating vessel (3). Example 5

[0014] In a method for physically treating malignant lymphoma, artemether C is placed in a blood-compatible metal tube (2) at the rear of a container (6) for returning to room temperature. 16 H 26 Adding O5(10) can further enhance the therapeutic effect of blood cancers such as leukemia and malignant lymphoma. Artemether is an artemisinin derivative that inhibits the proliferation of cancer cells. FIG. 5 is an explanatory diagram of the location where artemether (10) is added in the rear blood compatible metal tube (2) in the container (3) to be heated. [Industrial Applicability]

[0015] Unlike conventional medical treatments, this is a physical medical treatment that uses heat to treat viral hepatitis and blood cancer, which require long-term treatment. [Explanation of symbols]

[0016] 1 silicone tube 2. Heparin 3. Container to be heated 4 Hemophilic metal tube 5. Ozone 6. A container for returning the temperature to approximately 1°C higher than basal body temperature 7. Avigan 8. p53 protein 9 Serine / Threonine Residues and p300 / CBP 10 Artemether 11 Saltwater 12 Temperature Sensor

Claims

1. This is a method for physically treating pathogenic viruses such as hepatitis virus and blood cancers such as leukemia and malignant lymphoma. Venous blood is taken out of a venous blood vessel through a silicone tube (1), and immediately after adding heparin (2), the venous blood enters a container (3) that heats the blood to about 55-60°C. Ozone (5) is added to the blood as it circulates through a blood-compatible metal tube (4). After circulating further, the blood leaves the heated container (3) and enters a container (6) that returns the blood to a temperature about 1°C higher than the basal body temperature of each individual. The blood then passes through a network of blood-compatible metal tubes (4), leaves the container, and is returned to the human body. This is a treatment device for pathogenic viruses and blood cancers.

2. In the container (6) for returning to room temperature, ５ H ４ FN ３ O ２ 2. The therapeutic device for pathogenic viruses and blood cancers according to claim 1, further comprising (7).

3. A method for physically treating blood cancers such as leukemia and malignant lymphoma, characterized in that p53 protein (8) is added to the rear blood-compatible metal tube (2) in the heating container (3).

4. A method for physically treating blood cancers such as leukemia and malignant lymphoma, characterized in that serine / threonine residues and p300 / CBP (9) are added to the rear blood-compatible metal tube (2) in the heating container (3), as described in claim 1.

5. In a method for physically treating malignant lymphoma, a blood-compatible metal tube (2) is placed in a container (6) for returning to room temperature. １６ H ２６ O ５ 2. The therapeutic device for pathogenic viruses and blood cancers according to claim 1, further comprising (10).

Images